The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; A randomised, double-blind controlled trial

Journal of Diabetes and its Complications

Volumn 28, Issue 3, 2014, Pages 323-327

  Black, R Neil A ^a   Ennis, Cieran N ^a   Young, Ian S ^b   Hunter, Steven J ^a   Atkinson, A Brew ^a   Bell, Patrick M ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Fibrate; Insulin resistance; Peroxisome proliferator activated receptor alpha; Statin; Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; C PEPTIDE; CHOLESTEROL; CREATININE; FENOFIBRATE; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; TRIACYLGLYCEROL; URATE; ANTILIPEMIC AGENT; GLUCOSE BLOOD LEVEL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; AGONISTS; BLOOD; DOSE RESPONSE; GLUCOSE CLAMP TECHNIQUE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

BLOOD GLUCOSE; CHOLESTEROL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FENOFIBRATE; GLUCOSE CLAMP TECHNIQUE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PPAR ALPHA; PYRROLES;

EID: 84899514329     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2014.01.001     Document Type: Article

References (30)

1. G.M. Reaven Banting lecture 1988. Role of insulin resistance in human disease Diabetes 37 1988 1595 1607
2. E.A.M. Gale The myth of the metabolic syndrome Diabetologia 48 2005 1679 1683
3. B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: Nuclear control of metabolism Endocrine Reviews 20 1999 649 688
4. P.J. Randle, P.B. Garland, and C.N. Hales et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus Lancet 1 1963 785 789
5. G.W. Cline, K.F. Petersen, and M. Krssak et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes New England Journal of Medicine 341 1999 240 246
6. D.E. Kelley, and L.J. Mandarino Fuel selection in human skeletal muscle in insulin resistance: A re-examination Diabetes 49 2000 677 683
7. M. Guerre-Millo, P. Gervois, and E. Raspe et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity Journal of Biological Chemistry 275 2000 16638 16642
8. J. Rieusset, M. Roques, and K. Bouzakri et al. Regulation of p85alpha phosphatidylinositol-3-kinase expression by peroxisome proliferator-activated receptors (PPARs) in human muscle cells FEBS Letters 502 2001 98 102
9. M. Loviscach, N. Rehman, and L. Carter et al. Distribution of peroxisome proliferator activator receptors (PPARs) in human skeletal muscle and adipose tissue: Relation to insulin action Diabetologia 43 2000 304 311
10. R. Mukherjee, L. Jow, and D. Noonan et al. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators Journal of Steroid Biochemistry and Molecular Biology 51 1994 157 166
11. G. Riccardi, S. Genovese, and G. Saldalamacchia et al. Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes Atherosclerosis 75 1989 175 181
12. H. Vuorinen-Markkola, H. Yki-Jarvinen, and M.R. Taskinen Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 1993 161 169
13. J. Malik, V. Melenovsky, and D. Wichterle et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT) Cardiovascular Research 52 2001 290 298
14. Q. Wan, F. Wang, and F. Wang et al. Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: A prospective randomized controlled trial Diabetic Medicine 27 2010 1312 1317
15. C.M. Hwu, C.F. Kwok, and H.S. Chen et al. Lack of effect of simvastatin on insulin sensitivity in type 2 diabetic patients with hypercholesterolaemia: Results from a double-blind, randomised, placebo-controlled crossover study Diabetic Medicine 16 1999 749 754
16. J.A. Paniagua, J. Lopez-Miranda, and A. Escribano et al. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes Diabetes 51 2002 2596 2603
17. G. Paolisso, S. Sgambato, and S. De Riu et al. Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics European Journal of Clinical Pharmacology 40 1991 27 31
18. K.K. Koh, J.Y. Ahn, and M.J. Quon et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolaemia patients Diabetes Care 31 2008 776 782
19. J. Szendroedi, C. Anderwald, and M. Krssak et al. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients Diabetes Care 32 2009 209
20. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington et al. CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
21. A. Keech, R.J. Simes, and P. Barter et al. FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005:366:1849-61. Erratum in Lancet 368 2006 1415
22. ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus New England Journal of Medicine 362 2010 1563
23. R. Harper, C.N. Ennis, A.P. Heaney, and Sheridan et al. A comparison of the effects of low and conventional dose thiazide diuretic on insulin action in hypertensive patients with NIDDM Diabetologia 38 1995 853 859
24. R. Steele, J.S. Wall, and R.C. De Bodo et al. Measurement of size and turnover rate of body glucose pool by the isotope dilution method American Journal of Physiology 187 1956 15 24
25. R.C. De Bodo, R. Steele, and N. Altszuler et al. On the hormonal regulation of carbohydrate metabolism; studies with C14 glucose Recent Progress in Hormone Research 19 1963 445 488
26. M. Hills, and P. Armitage The two-period cross-over clinical trial British Journal of Clinical Pharmacology 8 1979 7 20
27. T.M. Willson, P.J. Brown, and D.D. Sternbach et al. The PPARs: From orphan receptors to drug discovery Journal of Medicinal Chemistry 43 2000 527 550
28. G. Martin, H. Duez, and C. Blanquart et al. Statin-induced inhibition of the Rho-signaling pathway activates PPAR-α and induces HDL apoA-I Journal of Clinical Investigation 107 2001 1423 1432
29. D.M. Flavell, H. Ireland, and J.W. Stephens et al. Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes Diabetes 54 2005 582 586
30. C. Harvengt, and F. Heller et al. Hypolipidaemic and hypouricaemia action of fenofibrate in various types of hyperlipoproteinaemias Artery 7 1980 73 82